AAPG on Nasdaq
ASCENTAGE PHARMA GROUP INTERNATIONAL
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with LIFECORE BIOMEDICAL, INC. \DE\, Xencor Inc or Karyopharm Therapeutics Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2024
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Products brought in 87% of the revenue ASCENTAGE PHARMA GROUP INTERNATIONAL broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Products | 193.5M CNY | 260.8M CNY | 499.3M CNY |
| Others | 28.4M CNY | 41.4M CNY | 74.8M CNY |
Where the money goes
Where each dollar of revenue went, fiscal 2024
- Other costs100¢$134.3M
Out of $134.3M in revenue.3 The company lost money this year.
Financial statements
No quarterly figures reported.
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenue | 574.1M CNY | 980.6M CNY | 222.0M CNY |
| Total cost of sales | -48.9M CNY | -29.1M CNY | -30.5M CNY |
| Gross profit | 525.2M CNY | 951.6M CNY | 191.4M CNY |
| Other income and gains | 103.5M CNY | 57.4M CNY | 59.3M CNY |
| Selling and distribution expenses | -353.6M CNY | -196.0M CNY | -195.4M CNY |
| Administrative expenses | -246.3M CNY | -187.1M CNY | -181.1M CNY |
| Research and development expenses | -1.1B CNY | -947.2M CNY | -707.0M CNY |
| Other expenses | -73.6M CNY | -9.1M CNY | -5.2M CNY |
| Finance costs | -54.1M CNY | -64.5M CNY | -96.1M CNY |
| Share of profit/(loss) of a joint venture | 314.0K CNY | -281.0K CNY | 1.1M CNY |
| LOSS BEFORE TAX | -1.2B CNY | -395.3M CNY | -932.9M CNY |
| Income tax credit/(expense) | -6.9M CNY | -10.4M CNY | 7.2M CNY |
| LOSS FOR THE YEAR | -1.2B CNY | -405.7M CNY | -925.7M CNY |
| Ordinary equity holders of the Company | -1.2B CNY | -405.4M CNY | -925.6M CNY |
| Non-controlling interests | -218.0K CNY | -247.0K CNY | -75.0K CNY |
| Basic (in Dollars per share and Yuan Renminbi per share) | -3.49 CNY | -1.34 CNY | -3.28 CNY |
| Diluted (in Dollars per share and Yuan Renminbi per share) | -3.49 CNY | -1.34 CNY | -3.28 CNY |
No quarterly figures reported.
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2025-01-31 | 2024-12-31 |
|---|---|---|---|
| Property, plant and equipment | 781.2M CNY | 849.5M CNY | |
| Right-of-use assets | 47.8M CNY | 56.1M CNY | |
| Goodwill | 24.7M CNY | 24.7M CNY | |
| Other intangible assets | 65.9M CNY | 76.0M CNY | |
| Investment in a joint venture | 33.0M CNY | 32.7M CNY | |
| Financial assets at fair value through profit or loss (FVTPL) | 4.0M CNY | 1.1M CNY | |
| Deferred tax assets | 32.0M CNY | 44.2M CNY | |
| Other non-current assets | 30.7M CNY | 59.3M CNY | |
| Total non-current assets | 1.0B CNY | 1.1B CNY | |
| Inventories | 28.6M CNY | 6.6M CNY | |
| Trade receivables, net | 252.9M CNY | 83.1M CNY | |
| Prepayments, other receivables and other assets | 192.5M CNY | 123.2M CNY | |
| Cash and bank balances | 2.5B CNY | 1.3B CNY | |
| Total current assets | 2.9B CNY | 1.5B CNY | |
| Trade payables | 106.7M CNY | 92.0M CNY | |
| Other payables and accruals | 276.7M CNY | 258.1M CNY | |
| Contract liabilities | 37.5M CNY | 37.5M CNY | |
| Interest-bearing bank and other borrowings | 1.2B CNY | 779.1M CNY | |
| Total current liabilities | 1.6B CNY | 1.2B CNY | |
| NET CURRENT ASSETS | 1.3B CNY | 307.6M CNY | |
| TOTAL ASSETS LESS CURRENT LIABILITIES | 2.3B CNY | 1.5B CNY | |
| Contract liabilities | 210.2M CNY | 248.5M CNY | |
| Interest-bearing bank and other borrowings | 757.2M CNY | 889.4M CNY | |
| Deferred tax liabilities | 5.4M CNY | ||
| Deferred income | 6.5M CNY | 27.5M CNY | |
| Other non-current liabilities | 12.0M CNY | 6.3M CNY | |
| Total non-current liabilities | 986.0M CNY | 1.2B CNY | |
| TOTAL LIABILITIES | 2.6B CNY | 2.3B CNY | |
| Ordinary shares (par value of US$0.0001 per share as of December 31, 2024 and 2025; 315,224,993 and 373,321,692 shares authorized, issued and outstanding as of December 31, 2024 and 2025, respectively) | 256.0K CNY | 15.0K CNY | 214.0K CNY |
| Treasury shares | -3.0M CNY | -8.0K CNY | |
| Share premium | 8.9B CNY | 6.5B CNY | |
| Capital and reserves | -397.3M CNY | -384.5M CNY | |
| Exchange fluctuation reserve | -179.1M CNY | -126.1M CNY | |
| Accumulated losses | -7.0B CNY | -5.8B CNY | |
| Equity attributable to ordinary equity holders of the Company | 1.3B CNY | 264.2M CNY | |
| Non-controlling interests | 9.8M CNY | 10.0M CNY | |
| Total equity | 1.3B CNY | 274.2M CNY | |
| Ordinary shares, par value (in Dollars per share) | $0.00 | $0.00 | |
| Ordinary shares, shares authorized (in Shares) | 373.3M shares | 315.2M shares | |
| Ordinary shares, shares issued (in Shares) | 373.3M shares | 315.2M shares | |
| Ordinary shares, shares outstanding (in Shares) | 373.3M shares | 315.2M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Loss before tax | -1.2B CNY | -395.3M CNY | -932.9M CNY |
| Depreciation of property, plant and equipment | 65.8M CNY | 71.2M CNY | 55.3M CNY |
| Depreciation of investment property | 15.9M CNY | ||
| Depreciation of right-of-use assets | 10.7M CNY | 11.1M CNY | 11.6M CNY |
| Amortization of intangible assets | 10.1M CNY | 10.9M CNY | 10.4M CNY |
| Equity-settled share-based payments | 20.9M CNY | 20.9M CNY | 31.5M CNY |
| (Gain)/loss on disposal of items of property, plant and equipment | 18.0K CNY | 50.0K CNY | -4.0K CNY |
| Gain on disposal of leases | -685.0K CNY | -85.0K CNY | |
| Fair value loss on financial assets measured at FVTPL | 1.1M CNY | 832.0K CNY | 699.0K CNY |
| Fair value loss on financial liabilities measured at FVTPL | 29.5M CNY | ||
| Fair value gain on derivative financial instruments | -2.8M CNY | ||
| Finance costs | 54.1M CNY | 64.5M CNY | 96.1M CNY |
| Share of (profit)/loss of a joint venture | -314.0K CNY | 281.0K CNY | -1.1M CNY |
| Provision for inventory write-down | 4.2M CNY | ||
| Foreign exchange (gain)/loss | 10.2M CNY | -6.7M CNY | -1.6M CNY |
| Total | -1.0B CNY | -222.3M CNY | -716.9M CNY |
| (Increase)/ Decrease in restricted cash balances | 18.9M CNY | -96.0K CNY | -7.9M CNY |
| (Increase)/Decrease in inventories | -26.2M CNY | 9.6M CNY | -6.7M CNY |
| (Increase)/Decrease in trade receivables | -169.8M CNY | 62.8M CNY | -91.5M CNY |
| Increase in prepayments, other receivables and other assets | -86.3M CNY | -14.4M CNY | -7.8M CNY |
| (Increase) /Decrease in other non-current assets | 27.8M CNY | -49.0M CNY | -3.6M CNY |
| (Decrease) /Increase in trade payables | 14.8M CNY | 19.5M CNY | -23.1M CNY |
| Increase in other payables and accruals | 113.8M CNY | 78.5M CNY | 48.6M CNY |
| Increase /(Decrease) in contract liabilities | -37.5M CNY | -3.7M CNY | 81.6M CNY |
| Increase in deferred income | 1.0M CNY | 7.7M CNY | 1.4M CNY |
| Income tax paid | -29.0K CNY | ||
| Net cash flows used in operating activities | -1.2B CNY | -111.4M CNY | -726.1M CNY |
| Purchases of property, plant and equipment | -27.6M CNY | -24.3M CNY | -46.1M CNY |
| Proceeds from disposal of property, plant and equipment | 14.0K CNY | ||
| Purchase of intangible assets | -10.7M CNY | ||
| Payment of contingent consideration related to acquisition of a subsidiary | -43.3M CNY | -9.5M CNY | -20.0M CNY |
| Maturity/(Placement) in time deposits with original maturity of more than three months | -925.1M CNY | -312.2M CNY | 98.8M CNY |
| Investment in other financial assets | -4.0M CNY | ||
| Investment in a joint venture | -16.0M CNY | ||
| Net cash flows generated from/ (used in) investing activities | -1.0B CNY | -362.0M CNY | 21.9M CNY |
| Proceeds from issue of shares | 2.3B CNY | 533.9M CNY | 470.1M CNY |
| Treasury share purchases | -9.0M CNY | -5.9M CNY | |
| Proceeds from exercise of share options | 4.0K CNY | 6.0K CNY | 8.0K CNY |
| Interest paid | -51.3M CNY | -60.6M CNY | -92.3M CNY |
| Proceeds from bank loans | 1.2B CNY | 535.9M CNY | 953.5M CNY |
| Repayment of bank loans | -924.0M CNY | -672.9M CNY | -956.1M CNY |
| Principal portion of lease payments | -9.7M CNY | -8.4M CNY | -10.8M CNY |
| Capital contribution from non-controlling shareholders of a subsidiary | 10.3M CNY | ||
| Listing expense paid | -11.7M CNY | -13.3M CNY | |
| Net cash flows generated from financing activities | 2.5B CNY | 314.8M CNY | 368.8M CNY |
| NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS | 365.9M CNY | -158.6M CNY | -335.4M CNY |
| Effect of foreign exchange rate changes, net | -63.2M CNY | 13.7M CNY | 27.8M CNY |
Compare ASCENTAGE PHARMA GROUP INTERNATIONAL with another company
Recent filings
- Sep 29, 20266-K REPORT OF FOREIGN PRIVATE ISSUER
- Sep 17, 20266-K REPORT OF FOREIGN PRIVATE ISSUER
- Aug 20, 20266-K REPORT OF FOREIGN PRIVATE ISSUER
- Aug 13, 20266-K REPORT OF FOREIGN PRIVATE ISSUER
- Aug 5, 20266-K REPORT OF FOREIGN PRIVATE ISSUER
- Aug 3, 20266-K REPORT OF FOREIGN PRIVATE ISSUER
- Jul 27, 20266-K REPORT OF FOREIGN PRIVATE ISSUER
- Jul 20, 2026F-3ASR REGISTRATION STATEMENT
- Jul 20, 20266-K REPORT OF FOREIGN PRIVATE ISSUER
- Jul 13, 20266-K REPORT OF FOREIGN PRIVATE ISSUER
- Jun 30, 20266-K REPORT OF FOREIGN PRIVATE ISSUER
- Jun 29, 20263 PRIMARY DOCUMENT
- Jun 15, 20266-K REPORT OF FOREIGN PRIVATE ISSUER
- Jun 12, 20266-K REPORT OF FOREIGN PRIVATE ISSUER
- Jun 10, 20266-K REPORT OF FOREIGN PRIVATE ISSUER
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4